{"hands_on_practices": [{"introduction": "The evaluation of hirsutism begins with a systematic and objective quantification of hair growth. This practice moves beyond a patient's subjective impression to a standardized clinical assessment using the Modified Ferriman–Gallwey (mFG) scoring system. This exercise [@problem_id:4449308] provides a direct application of this essential tool, challenging you to calculate a patient's mFG score from area-specific data and interpret it against an ethnicity-specific threshold, a fundamental skill for diagnosing and grading hirsutism.", "problem": "A clinician is evaluating a patient of European ancestry for excessive terminal hair growth using the Modified Ferriman–Gallwey (mFG) scoring system. The Modified Ferriman–Gallwey (mFG) score is defined as the sum of individual terminal hair scores assigned to nine androgen-sensitive body areas, each graded from $0$ (no terminal hairs) to $4$ (extensive terminal hair growth), based on standardized inspection. Ethnicity-specific thresholds are used to interpret the total, with a commonly accepted threshold for European ancestry of $8$, above which hirsutism is considered present.\n\nOn standardized examination, the patient’s nine area scores are $3, 2, 2, 1, 3, 2, 1, 2, 1$ (each score corresponds to one of the nine sites). Using the definition that the total mFG score $S$ equals the sum of the nine area scores, and defining the exceedance indicator $I$ by\n$$\nI=\\begin{cases}\n1 & \\text{if } S>8,\\\\\n0 & \\text{if } S\\le 8,\n\\end{cases}\n$$\ncompute $S$ and $I$. Report your final result as a row matrix containing $S$ and $I$. No rounding is required. No units are to be included in the final answer.", "solution": "The problem requires the computation of two values, the Modified Ferriman–Gallwey (mFG) score $S$ and an exceedance indicator $I$, based on a set of provided clinical scores. Before proceeding with the solution, a rigorous validation of the problem statement is necessary.\n\nThe validation proceeds in three steps:\n1.  **Extract Givens**: Listing all explicitly provided information.\n2.  **Validate Using Extracted Givens**: Assessing the problem for scientific soundness, consistency, and clarity.\n3.  **Verdict and Action**: Determining whether to solve the problem or declare it invalid.\n\n**Step 1: Extract Givens**\nThe following information is explicitly provided in the problem statement:\n- The patient is of European ancestry.\n- The evaluation uses the Modified Ferriman–Gallwey (mFG) scoring system.\n- The total mFG score, denoted by $S$, is the sum of scores from nine androgen-sensitive body areas.\n- Each area is graded from $0$ to $4$.\n- The threshold for hirsutism in this population is a score greater than $8$.\n- The patient's nine individual area scores are: $3, 2, 2, 1, 3, 2, 1, 2, 1$.\n- The total score $S$ is defined as the sum of these nine scores.\n- The exceedance indicator $I$ is defined by the piecewise function:\n$$\nI=\\begin{cases}\n1 & \\text{if } S>8,\\\\\n0 & \\text{if } S\\le 8,\n\\end{cases}\n$$\n- The final result must be reported as a row matrix containing $S$ and $I$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is assessed against the criteria for validity:\n- **Scientific Groundedness**: The problem is grounded in established clinical practice. The mFG score is the most widely used method for quantifying hirsutism. The scoring system ($0$ to $4$ per site), the number of sites ($9$), and the use of ethnicity-specific thresholds are all standard components of this clinical tool. The specified threshold of $8$ is a commonly cited value for women of European descent. The problem is directly relevant to its stated field and topic (*hirsutism: evaluation and management* within *obstetrics and gynecology*). The problem is scientifically sound.\n- **Well-Posedness**: The problem provides all necessary data (the nine scores) and clear, unambiguous definitions for the quantities to be calculated ($S$ and $I$). The operations required (summation and comparison) are elementary and lead to a unique, stable solution. The problem is well-posed.\n- **Objectivity**: The problem is stated in precise, objective language. The scores are given as numerical data, and the definitions of $S$ and $I$ are formal mathematical expressions. There is no subjective or opinion-based content.\n\nThe problem exhibits no flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity. While the required calculation is simple, the problem is a valid application of quantitative methods in a biomedical context, not a trivial exercise devoid of substance.\n\n**Step 3: Verdict and Action**\nThe problem is deemed **valid**. The solution process will now be executed.\n\n**Solution**\nThe first step is to compute the total Modified Ferriman–Gallwey score, $S$. This score is defined as the sum of the nine individual area scores provided.\nLet the individual scores be denoted by $s_i$ for $i=1, 2, \\dots, 9$. The given scores are:\n$s_1 = 3$\n$s_2 = 2$\n$s_3 = 2$\n$s_4 = 1$\n$s_5 = 3$\n$s_6 = 2$\n$s_7 = 1$\n$s_8 = 2$\n$s_9 = 1$\n\nThe total score $S$ is the sum of these scores:\n$$S = \\sum_{i=1}^{9} s_i$$\nSubstituting the given values:\n$$S = 3 + 2 + 2 + 1 + 3 + 2 + 1 + 2 + 1$$\nPerforming the addition:\n$$S = (3 + 2) + (2 + 1) + (3 + 2) + (1 + 2) + 1$$\n$$S = 5 + 3 + 5 + 3 + 1$$\n$$S = 8 + 8 + 1$$\n$$S = 17$$\n\nThe second step is to determine the value of the exceedance indicator, $I$. The value of $I$ depends on whether $S$ is greater than the threshold of $8$. The formal definition is:\n$$\nI=\\begin{cases}\n1 & \\text{if } S>8,\\\\\n0 & \\text{if } S\\le 8,\n\\end{cases}\n$$\nWe have calculated $S = 17$. We compare this value to the threshold $8$:\n$$17 > 8$$\nSince the condition $S > 8$ is true, the value of the indicator $I$ is $1$.\n$$I = 1$$\n\nThe problem requires the final result to be reported as a row matrix containing $S$ and $I$. The matrix is therefore:\n$$\\begin{pmatrix} S & I \\end{pmatrix}$$\nSubstituting the calculated values for $S$ and $I$:\n$$\\begin{pmatrix} 17 & 1 \\end{pmatrix}$$\nThis means the patient's mFG score is $17$, which is above the threshold of $8$, indicating the presence of hirsutism according to this specific criterion, and thus the indicator $I$ is $1$.", "answer": "$$\\boxed{\\begin{pmatrix} 17 & 1 \\end{pmatrix}}$$", "id": "4449308"}, {"introduction": "Once clinical hyperandrogenism is documented, the next step is to confirm the underlying biochemical androgen excess. However, total testosterone levels alone can be misleading, as hormone activity is determined by the unbound, or free, fraction. This practice [@problem_id:4449276] demonstrates how to calculate the Free Androgen Index (FAI), a widely used and accessible tool that provides a more accurate reflection of bioactive androgen status by accounting for the concentration of Sex Hormone-Binding Globulin (SHBG).", "problem": "A reproductive-age patient presents with progressive terminal hair growth on the chin and lower abdomen over the past year, with a modified Ferriman–Gallwey score of $18$. The patient has regular ovulatory cycles, body mass index of $29$, and no exogenous androgen exposure. Morning serum total testosterone measured by liquid chromatography–tandem mass spectrometry is $1.8\\ \\mathrm{nmol/L}$, and sex hormone–binding globulin (SHBG) measured by immunoassay is $18\\ \\mathrm{nmol/L}$, both obtained in the follicular phase. \n\nFrom a pathophysiologic standpoint, circulating androgens are partitioned among free, SHBG-bound (high affinity), and albumin-bound (low affinity) pools according to the law of mass action. When equilibrium dialysis or equilibrium calculations are not available, a widely used operational index to approximate the free androgen exposure uses the measured total testosterone and SHBG obtained in the same molar units. Assume the laboratory’s medical decision threshold for biochemical hyperandrogenism in premenopausal women is an index value strictly greater than $5$.\n\nUsing only the data provided, compute the free androgen index and report it as a pure number without a percent sign. Round your answer to three significant figures. Then, based on the provided threshold, determine whether the result indicates biochemical hyperandrogenism in this premenopausal patient. Do not include your interpretation in the final numeric answer.", "solution": "The problem requires the computation of the Free Androgen Index (FAI) and a determination of whether the result signifies biochemical hyperandrogenism based on a provided threshold.\n\nThe Free Androgen Index is an operational measure used to estimate the amount of biologically active free testosterone. It is calculated as the ratio of the total testosterone concentration to the sex hormone–binding globulin (SHBG) concentration, multiplied by a factor of $100$. The formula is:\n$$ \\text{FAI} = \\frac{[\\text{Total Testosterone}]}{[\\text{SHBG}]} \\times 100 $$\nFor this formula to be valid, both concentrations must be in the same molar units.\n\nThe problem provides the following data:\n- Total Testosterone concentration, $[\\text{T}] = 1.8\\ \\mathrm{nmol/L}$.\n- Sex Hormone–Binding Globulin concentration, $[\\text{SHBG}] = 18\\ \\mathrm{nmol/L}$.\n\nThe units are consistent (nmol/L), so we can proceed with the calculation. Substituting the given values into the formula:\n$$ \\text{FAI} = \\frac{1.8}{18} \\times 100 $$\nFirst, we compute the ratio:\n$$ \\frac{1.8}{18} = 0.1 $$\nNext, we multiply by $100$:\n$$ \\text{FAI} = 0.1 \\times 100 = 10 $$\nThe problem instructs to report the answer rounded to three significant figures. The calculated value is exactly $10$. To express this with three significant figures, we write it as $10.0$.\n\nThe second part of the task is to determine if this result indicates biochemical hyperandrogenism. The problem provides the laboratory's medical decision threshold: an index value strictly greater than $5$.\nOur calculated Free Androgen Index is:\n$$ \\text{FAI} = 10.0 $$\nWe compare this value to the threshold of $5$:\n$$ 10.0 > 5 $$\nSince the calculated FAI of $10.0$ is strictly greater than the threshold of $5$, the result indicates the presence of biochemical hyperandrogenism in this patient according to the specified criterion. This biochemical finding is consistent with the patient's clinical presentation of hirsutism (modified Ferriman–Gallwey score of $18$, where a score $\\ge 8$ is typically considered indicative of hirsutism). The final numeric answer should only contain the computed index value as requested.", "answer": "$$\\boxed{10.0}$$", "id": "4449276"}, {"introduction": "Effective management of hirsutism requires not only initiating therapy but also systematically evaluating its success over time. This exercise [@problem_id:4449230] simulates a realistic follow-up scenario, tasking you with applying predefined outcome measures, known as Minimal Clinically Important Differences (MCIDs), to classify a patient's response as a success, partial response, or failure. Mastering this approach is crucial for making evidence-based decisions about continuing, escalating, or changing treatment, ensuring that management is aligned with clinically meaningful patient-centered outcomes.", "problem": "A $24$-year-old nulligravid woman with polycystic ovary syndrome (PCOS) presents with bothersome facial hirsutism affecting quality of life. At baseline, her modified Ferriman–Gallwey (mFG) score was $22$, and she reported spending $90$ minutes per week on facial hair removal. She was started on a combined oral contraceptive pill (COCP) plus spironolactone $50$ mg twice daily, with counseling that clinical effects lag behind biochemical changes because reduction in new terminal hair follows the facial hair cycle anagen length of approximately $4$ months and that meaningful cosmetic change typically requires at least $6$ months. Your clinic’s quality program has pre-specified minimal clinically important differences (MCIDs) to define outcome categories at $6$ months as follows:\n- Primary MCID: mFG reduction of at least $30\\%$ from baseline by $6$ months.\n- Secondary MCID: at least $30\\%$ reduction in weekly hair removal time or a Patient Global Impression of Change (PGIC) of “much improved” or better.\n- Response categories at $6$ months: “success” if the primary MCID is met (regardless of secondary) or if both secondary MCIDs are met; “partial response” if mFG reduction is between $10\\%$ and $29\\%$ or if a single secondary MCID is met without the primary; “treatment failure” if mFG reduction is less than $10\\%$ and no secondary MCID is met.\n\nAt $6$ months, her mFG score is $17$, weekly hair removal time is $65$ minutes, serum total testosterone has decreased modestly within the reference range, and her PGIC is “a little better.” She denies missed pills, states adherence above $90\\%$, has normal serum potassium, and does not desire pregnancy.\n\nWhich of the following best classifies her response and outlines the most appropriate next step, integrating the above definitions with the biology of hair growth and the expected time course of antiandrogen effect?\n\nA. Classify as treatment failure and switch spironolactone to finasteride now; add topical eflornithine and plan to reassess at $3$ months.\n\nB. Classify as partial response; continue the current COCP and spironolactone through $9$–$12$ months with counseling on expectation of delayed maximal effect; offer adjunct local measures such as laser hair reduction or topical eflornithine; consider dose escalation if plateau by $9$–$12$ months.\n\nC. Classify as success; maintain the current regimen without changes and reduce follow-up to annual visits.\n\nD. Classify as biochemical success based on improved testosterone and immediately increase spironolactone to target at least $50\\%$ mFG reduction by $6$ months because biochemical targets take precedence over clinical MCIDs.", "solution": "The user wants me to act as a meticulous STEM professor and solve a clinical problem about hirsutism management. I must first validate the problem statement, and if it is valid, proceed to a detailed solution and evaluation of all options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n- **Patient Profile:** A $24$-year-old nulligravid woman with polycystic ovary syndrome (PCOS).\n- **Baseline Condition:**\n  - Modified Ferriman–Gallwey (mFG) score = $22$.\n  - Weekly facial hair removal time = $90$ minutes.\n- **Intervention:** Combined oral contraceptive pill (COCP) plus spironolactone $50$ mg twice daily (total daily dose of $100$ mg).\n- **Counseling Provided:**\n  - Clinical effects on hair lag biochemical changes.\n  - Facial hair cycle anagen length is approximately $4$ months.\n  - Meaningful cosmetic change requires at least $6$ months.\n- **Outcome Definitions at $6$ months (Minimal Clinically Important Differences - MCIDs):**\n  - **Primary MCID:** mFG reduction $\\ge 30\\%$ from baseline.\n  - **Secondary MCID:** (at least one of the following)\n    1.  Weekly hair removal time reduction $\\ge 30\\%$.\n    2.  Patient Global Impression of Change (PGIC) of “much improved” or better.\n- **Response Categories at $6$ months:**\n  - **\"Success\":** Primary MCID is met, OR both secondary MCIDs are met.\n  - **\"Partial response\":** mFG reduction is between $10\\%$ and $29\\%$, OR a single secondary MCID is met without the primary.\n  - **\"Treatment failure\":** mFG reduction $< 10\\%$ AND no secondary MCID is met.\n- **Follow-up Data at $6$ months:**\n  - mFG score = $17$.\n  - Weekly hair removal time = $65$ minutes.\n  - Serum total testosterone: decreased modestly.\n  - PGIC: “a little better”.\n  - Adherence and safety: Adherence > $90\\%$, normal serum potassium.\n  - Patient goals: Does not desire pregnancy.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem statement is evaluated against the validation criteria.\n\n- **Scientifically Grounded:** The problem is firmly based on established medical science in endocrinology and gynecology. The pathophysiology of hirsutism in PCOS, the pharmacology of COCPs and spironolactone, the principles of hair growth biology (anagen phase), and the use of standardized clinical tools (mFG score, PGIC, MCID) are all accurate and standard in the field.\n- **Well-Posed:** The problem is well-posed. It provides all necessary numerical data (baseline and follow-up values) and a clear, hierarchical set of logical rules for classifying the patient's response. The question asks for a classification and a subsequent management step, which can be uniquely determined by applying these rules and established clinical principles.\n- **Objective:** The language is clinical and objective. The criteria for success, partial response, and failure are quantitatively and qualitatively defined, leaving no room for subjective interpretation by the solver.\n\nThe problem does not exhibit any of the invalidity flaws. It is factually sound, complete, realistic, and well-structured.\n\n**Step 3: Verdict and Action**\n\nThe problem is **valid**. The solution process will now proceed.\n\n### Solution Derivation\n\nThe solution requires a two-part process: first, classifying the patient's response according to the provided definitions, and second, determining the most appropriate next step based on this classification and the underlying biological principles.\n\n**Part 1: Classification of Response**\n\nWe must systematically check the patient's $6$-month outcomes against the MCID criteria.\n\n1.  **Evaluate Primary MCID (mFG Reduction):**\n    - Baseline mFG score: $S_0 = 22$.\n    - $6$-month mFG score: $S_6 = 17$.\n    - Absolute reduction: $\\Delta S = S_0 - S_6 = 22 - 17 = 5$.\n    - Percentage reduction: $\\% \\Delta S = \\frac{\\Delta S}{S_0} \\times 100\\% = \\frac{5}{22} \\times 100\\% \\approx 22.73\\%$.\n    - The criterion for the primary MCID is a reduction of at least $30\\%$. Since $22.73\\% < 30\\%$, the **primary MCID is not met**.\n\n2.  **Evaluate Secondary MCIDs:**\n    - **Hair Removal Time Reduction:**\n      - Baseline time: $T_0 = 90$ minutes/week.\n      - $6$-month time: $T_6 = 65$ minutes/week.\n      - Absolute reduction: $\\Delta T = T_0 - T_6 = 90 - 65 = 25$ minutes/week.\n      - Percentage reduction: $\\% \\Delta T = \\frac{\\Delta T}{T_0} \\times 100\\% = \\frac{25}{90} \\times 100\\% \\approx 27.78\\%$.\n      - The criterion is a reduction of at least $30\\%$. Since $27.78\\% < 30\\%$, this **secondary MCID is not met**.\n    - **PGIC Score:**\n      - The patient's reported PGIC is “a little better”.\n      - The criterion is a score of “much improved” or better.\n      - Therefore, this **secondary MCID is not met**.\n\n3.  **Apply Response Category Definitions:**\n    - **\"Success\":** This requires either the primary MCID to be met (it was not) OR both secondary MCIDs to be met (neither was met). Thus, the response is **not a \"success\"**.\n    - **\"Treatment failure\":** This requires mFG reduction to be less than $10\\%$ AND no secondary MCID to be met. The mFG reduction was $22.73\\%$, which is not less than $10\\%$. Although the second condition (no secondary MCID met) is true, the first condition is false. The logical operator is AND, so the combined statement is false. Thus, the response is **not a \"treatment failure\"**.\n    - **\"Partial response\":** This requires mFG reduction between $10\\%$ and $29\\%$ OR a single secondary MCID to be met. The mFG reduction was $22.73\\%$, which is indeed between $10\\%$ and $29\\%$. Because this condition is met, the response is classified as a **\"partial response\"**.\n\n**Conclusion of Part 1:** The patient's response is a \"partial response\".\n\n**Part 2: Determination of the Next Step**\n\nBased on the classification of \"partial response\" and the biological context provided:\n\n- The patient is showing a definite, measurable clinical improvement ($22.73\\%$ mFG reduction) after $6$ months.\n- The problem statement explicitly reminds us that \"meaningful cosmetic change typically requires at least $6$ months\" and that the full benefit is delayed due to the hair growth cycle. Maximal effects of antiandrogen therapy are often not seen until $9$–$12$ months of continuous treatment.\n- The patient is adherent and tolerating the medication well (normal potassium).\n- Therefore, discontinuing or switching a therapy that is clearly working, albeit partially at this early checkpoint, would be inappropriate. The most logical course of action is to continue the current treatment to allow time for the maximal effect to be achieved.\n- Offering adjunctive therapies like laser/light-based hair removal or topical eflornithine is a standard and recommended component of management, as these provide more rapid cosmetic improvement while awaiting the full effect of systemic therapy.\n- Considering a dose escalation of spironolactone (e.g., to $75$ mg or $100$ mg twice daily) is a valid future strategy if the response plateaus, but it is reasonable to wait until the $9$–$12$ month mark to make this determination.\n\n### Option-by-Option Analysis\n\n**A. Classify as treatment failure and switch spironolactone to finasteride now; add topical eflornithine and plan to reassess at $3$ months.**\n- **Classification:** Incorrect. The response is a \"partial response,\" not a \"treatment failure,\" based on the provided definitions. The mFG reduction of $22.73\\%$ is well above the $<10\\%$ threshold for failure.\n- **Next Step:** Incorrect. Switching from spironolactone, which is showing efficacy, is premature at $6$ months. The biological rationale for delayed effect argues for continuing the current regimen.\n\n**B. Classify as partial response; continue the current COCP and spironolactone through $9$–$12$ months with counseling on expectation of delayed maximal effect; offer adjunct local measures such as laser hair reduction or topical eflornithine; consider dose escalation if plateau by $9$–$12$ months.**\n- **Classification:** Correct. As derived above, the response meets the definition of \"partial response.\"\n- **Next Step:** Correct. This plan is fully consistent with the biological principles of hair growth and the standard of care for hirsutism. It acknowledges the partial success, respects the time course of therapy, reinforces patient counseling, and provides a sound multi-modal and long-term strategy.\n\n**C. Classify as success; maintain the current regimen without changes and reduce follow-up to annual visits.**\n- **Classification:** Incorrect. The response did not meet the criteria for \"success.\"\n- **Next Step:** Incorrect. Reducing follow-up to annually is inappropriate for a patient with a partial response who requires continued monitoring to assess for maximal benefit and potential need for therapy optimization.\n\n**D. Classify as biochemical success based on improved testosterone and immediately increase spironolactone to target at least $50\\%$ mFG reduction by $6$ months because biochemical targets take precedence over clinical MCIDs.**\n- **Classification:** Incorrect. The problem provides a specific clinical classification scheme; \"biochemical success\" is not a defined category.\n- **Next Step:** Incorrect. The primary goal of hirsutism treatment is clinical improvement, not normalization of a lab value. The problem explicitly states that clinical effects lag biochemical ones, invalidating the argument to act based on biochemistry over the observed clinical trend. Furthermore, targeting an arbitrary $50\\%$ reduction is not supported by the problem's provided MCID framework. The entire rationale is flawed.", "answer": "$$\\boxed{B}$$", "id": "4449230"}]}